Editors
Fatima Cardoso, MD, PhD
Breast Unit, Champalimaud Clinical Centre/Champalimaud Foundation, Lisbon, Portugal
Dr Cardoso is the Director of the Breast Unit of the Champalimaud Clinical Centre (CCC) in Lisbon, Portugal. She is board-certified in medical oncology and internal medicine, having earned her medical degree at the University of Porto, Portugal; she completed fellowships at the Jules Bordet Institute (IJB), Brussels, Belgium and at the MD Anderson Cancer Center, Houston, Texas, USA. She worked for 10 years as Assistant Professor at IJB and returned to Portugal in 2010 to create the Breast Unit of the CCC, the first certified Breast Unit in Portugal.
Her research interests include the biology of breast cancer, prognostic and predictive markers, new anticancer agents and clinical trials. She is also deeply involved in global cancer policy and is the founder and president of the Advanced Breast Cancer (ABC) Global Alliance and the ABC International Consensus Guidelines. She is active in many professional organisations such as the European School of Oncology (ESO), the European Society for Medical Oncology (ESMO), the American Society of Clinical Oncology (ASCO), the American Association for Cancer Research (AACR), the European Organisation for Research and Treatment of Cancer (EORTC) and the European Cancer Organisation (ECO), where she serves on several committees, and is the Editor-in-Chief of The Breast.
Dr Cardoso has received several educational and research grants, including funding from the European Union and the Bertarelli Rare Cancers Fund, and has authored about 380 publications. She has received several awards, including the prestigious Order of Santiago da Espada for Scientific Merit from the President of Portugal, the 2020 European Breast Cancer Science Award, the 2021 Umberto Veronesi Memorial Award and the 2022 ESMO Women for Oncology Award.
Vivianne Tjan-Heijnen, MD, PhD
Department of Medical Oncology, Maastricht University Medical Center (MUMC+) Comprehensive Cancer Center, Maastricht, Netherlands
Professor Tjan-Heijnen obtained her medical degree from Radboud University, Nijmegen, Netherlands. She currently works as a medical oncologist at MUMC+ Comprehensive Cancer Center, Maastricht, Netherlands. Her main field of interest is breast cancer, more specifically focusing on young women with a wish for fertility preservation, and on metastatic breast cancer.
She is the past president of the National Breast Cancer Organisation of the Netherlands and initiated the NABON Breast Cancer Audit, which annually assesses the quality of breast cancer care in Dutch hospitals. She was chair of the Dutch committee for the assessment of oncological drugs (BOM) and initiator and first director of the Comprehensive Cancer Network South-East Netherlands (OncoZON), involving 11 institutes (2010–2015).
Currently, Professor Tjan-Heijnen chairs the metastatic breast cancer team within OncoZON. Her research focuses on quality of care in daily practice and cost-effective implementation of new treatments. She initiated several Dutch breast cancer studies (Two-to-Six, INTENS, DATA, MIRROR, SONABRE) and is involved in many international studies. She has (co)authored over 300 peer-reviewed full papers and has been the supervisor of 50 PhD students.
Ivana Božović-Spasojević, MD, PhD
Daily Chemotherapy Hospital, Institute for Oncology and Radiology, Belgrade, Serbia
Dr Božović-Spasojević is the Head of the Daily Chemotherapy Hospital at the Institute for Oncology and Radiology, Belgrade, Serbia. She is a European School of Oncology (ESO)-certified breast cancer sub-specialist, with extensive expertise in internal medicine and medical oncology, and holds a Certificate of Competence in Breast Cancer from Ulm University, Ulm, Germany.
She has a background as a former Translational Research Fellow at the Breast International Group (TRANSBIG) and served as a medical advisor and Clinical Research Fellow at the Jules Bordet Institute, Brussels, Belgium. Since 2015, she has been a member of the National Expert Commission for Oncology at the Ministry of Health of the Republic of Serbia, and contributes to the Ethics Committee of Serbia for clinical research and the Medicines and Medical Devices Agency of Serbia for oncology drug registration.
Dr Božović-Spasojević graduated from the European Society for Medical Oncology (ESMO) Leaders Generation Programme in 2018, and is an active leader in oncology communities, serving as co-chair of the ESMO–SIOPE (European Society for Paediatric Oncology) Adolescent and Young Adults Working Group, and as deputy chair of the ESMO Educational Publications Working Group. She is also a member of the steering committee of the Serbian Society of Medical Oncology and serves as a scientific director in the Certificate of Competence in Breast Cancer programme at ESO.
Marta Vaz Batista, MD
Hospital Professor Doutor Fernando Fonseca, Amadora, Portugal
Dr Vaz Batista is a Medical Oncologist at Hospital Professor Doutor Fernando Fonseca, Amadora, Portugal. She completed her Master´s Degree in Medicine at Faculdade de Medicina da Universidade de Lisboa, Lisbon, Portugal in 2014 and her residency in Medical Oncology in 2021. She has completed postgraduate studies in nutrition in oncology and her areas of interest are breast cancer, gynaecological cancer and clinical trials.
Dr Vaz Batista is passionate about bringing innovation to daily practice, working with special interest in clinical trials focusing on breast cancer, brain metastasis and leptomeningeal carcinomatosis from breast cancer and other solid tumours. She is one of the authors and the medical monitor of the DEBBRAH phase II study, a clinical trial evaluating the role of trastuzumab deruxtecan in patients with HER2-positive or HER2 low-expressing metastatic breast cancer with brain metastases and/or leptomeningeal carcinomatosis. She also collaborates on other clinical trials.
She has been a member of the European Society for Medical Oncology (ESMO) since 2015 and joined the ESMO Educational Publications Working Group in January 2022.
Authors:
Part A. What every oncologist should know
Chapter 1. Screening, diagnosis & staging of breast cancer and multidisciplinary team working
- H. Joensuu, Comprehensive Cancer Center, Helsinki University Hospital and University of Helsinki, Helsinki, Finland
- T. Meretoja, Comprehensive Cancer Center, Helsinki University Hospital and University of Helsinki, Helsinki, Finland
Chapter 2. Pathology (including normal breast) and disease subtypes
- M.G. Mastropasqua, Department of Precision and Regenerative Medicine and Ionian Area, University of Bari Aldo Moro, School of Medicine, Bari, Italy
- G. Viale, Department of Pathology and Laboratory Medicine, European Institute of Oncology IRCCS, Milan, Italy
Chapter 3. Management of carcinoma in situ
- M.-J. Cardoso, Breast Unit, Champalimaud Clinical Centre/Champalimaud Foundation, Lisbon, Portugal
- I. Meattini, Department of Experimental and Clinical Biomedical Sciences ‘M. Serio’, University of Florence, Florence, Italy
Chapter 4. Breast cancer surgery
- J.A.F. van Rooij, Department of Plastic, Reconstructive and Hand Surgery, Maastricht University Medical Center (MUMC+), Maastricht; GROW, School for Oncology and Reproduction, Faculty of Health, Medicine and Life Sciences, Maastricht University, Maastricht, Netherlands
- M.T.F.D. Vrancken Peeters, Department of Surgery, Netherlands Cancer Institute – Antoni van Leeuwenhoek, Amsterdam; Department of Surgery, Amsterdam University Medical Center, Amsterdam, Netherlands
- M. de Henau, Department of Plastic, Reconstructive and Hand Surgery, Maastricht University Medical Center (MUMC+), Maastricht; GROW, School for Oncology and Reproduction, Faculty of Health, Medicine and Life Sciences, Maastricht University, Maastricht, Netherlands
- M.L. Smidt, GROW, School for Oncology and Reproduction, Faculty of Health, Medicine and Life Sciences, Maastricht University, Maastricht; Department of Surgery, Maastricht University Medical Center (MUMC+), Maastricht, Netherlands
Chapter 5. Breast cancer radiotherapy
- M.L.H. Milo, Department of Oncology, Aalborg University Hospital, Aalborg, Denmark
- B.V. Offersen, Department of Experimental Clinical Oncology, Department of Oncology, Danish Centre for Particle Therapy, Aarhus; University Hospital Clinical Medicine, Aarhus University, Aarhus, Denmark
Chapter 6. Early HER2-positive breast cancer: systemic therapy
- C. Pottier, Medical Oncology Department, Centre Hospitalier Universitaire (CHU) de Liège, Liège, Belgium
- G. Jerusalem, Medical Oncology Department, Centre Hospitalier Universitaire (CHU) de Liège and Liège University, Liège, Belgium
Chapter 7. Early triple-negative breast cancer: systemic therapy
- J.Z.C. Tan, Division of Medical Oncology, National Cancer Centre Singapore, Singapore
- J.J. Chan, Division of Medical Oncology, National Cancer Centre Singapore, Singapore
- R.A. Dent, Division of Medical Oncology, National Cancer Centre Singapore, Singapore
- T.J. Tan, Division of Medical Oncology, National Cancer Centre Singapore, Singapore
Chapter 8. Early ER-positive, HER2-negative breast cancer: systemic therapy
- L. Biganzoli, Department of Oncology, Hospital of Prato, Azienda USL Toscana Centro, Prato, Italy
- A. McCartney, School of Clinical Sciences, Monash University, Melbourne; Department of Medical Oncology, Monash Health, Melbourne, VIC, Australia
Chapter 9. Metastatic HER2-positive breast cancer: systemic therapy
- N. Cichowska-Cwalińska, Department of Oncology and Radiotherapy, Medical University of Gdańsk; Early Phase Clinical Trials Centre, Medical University of Gdańsk, Gdańsk, Poland
- E. Senkus, Department of Oncology and Radiotherapy, Medical University of Gdańsk, Gdańsk, Poland
Chapter 10. Metastatic triple-negative breast cancer: systemic therapy
- C. Corti, Division of New Drugs and Early Drug Development for Innovative Therapies, European Institute of Oncology, IRCCS, Milan; Department of Oncology and Hematology-Oncology (DIPO), University of Milan, Milan, Italy
- G. Antonarelli, Division of New Drugs and Early Drug Development for Innovative Therapies, European Institute of Oncology, IRCCS, Milan; Department of Oncology and Hematology-Oncology (DIPO), University of Milan, Milan, Italy
- C. Valenza, Division of New Drugs and Early Drug Development for Innovative Therapies, European Institute of Oncology, IRCCS, Milan; Department of Oncology and Hematology-Oncology (DIPO), University of Milan, Milan, Italy
- G. Curigliano, Division of New Drugs and Early Drug Development for Innovative Therapies, European Institute of Oncology, IRCCS, Milan; Department of Oncology and Hematology-Oncology (DIPO), University of Milan, Milan, Italy
Chapter 11. Metastatic ER-positive, HER2-negative breast cancer: systemic therapy
- A. Hester, Breast Center, Department of Obstetrics and Gynecology, CCC Munich and BZKF, LMU University Hospital, LMU Munich, Munich, Germany
- N. Harbeck, Breast Center, Gynecologic Cancer Center, Department of Obstetrics and Gynecology, CCC Munich and BZKF, LMU University Hospital, LMU Munich, Munich, Germany
- R. Wuerstlein, Breast Center, Gynecologic Cancer Center, Department of Obstetrics and Gynecology, CCC Munich and BZKF, LMU University Hospital, LMU Munich, Munich, Germany
Part B. More advanced knowledge
Chapter 12. Epidemiology of breast cancer
- V. Lope, Cancer and Environmental Epidemiology Unit, National Center of Epidemiology, Instituto de Salud Carlos III (ISCIII), Madrid; Consortium for Biomedical Research in Epidemiology and Public Health (CIBERESP), ISCIII, Madrid, Spain
- M. Pollán, Cancer and Environmental Epidemiology Unit, National Center of Epidemiology, Instituto de Salud Carlos III (ISCIII), Madrid; Consortium for Biomedical Research in Epidemiology and Public Health (CIBERESP), ISCIII, Madrid, Spain
Chapter 13. Genetic counselling and testing
- S. Paluch-Shimon, Sharett Institute of Oncology, Hadassah University Hospital & Faculty of Medicine Hebrew University, Ein Kerem, Jerusalem, Israel
- Y.B. Wygoda, Sharett Institute of Oncology, Hadassah University Hospital & Faculty of Medicine Hebrew University, Ein Kerem, Jerusalem, Israel
Chapter 14. Prognostic and predictive factors
- F. Penault-Llorca, Département de Pathologie et de Pathologie Moléculaire, Centre Jean Perrin, Clermont-Ferrand, France
Chapter 15. Organ-specific problems in metastatic breast cancer
- A. Gennari, Medical Oncology, University of Eastern Piedmont, Novara, Italy
- M. La Commare, Medical Oncology, Istituto Oncologico Veneto IRCCS, Padova, Italy
Chapter 16. Breast cancer in men
- F. Cardoso, Breast Unit, Champalimaud Clinical Centre/Champalimaud Foundation, Lisbon, Portugal
- B. Sousa, Breast Unit, Champalimaud Clinical Centre/Champalimaud Foundation, Lisbon, Portugal
Chapter 17. Breast cancer in young women
- L. Arecco, Department of Internal Medicine and Medical Specialties (DiMI), School of Medicine, University of Genova, Genoa; Department of Medical Oncology, U.O.C. Clinica di Oncologia Medica, IRCCS Ospedale Policlinico San Martino, Genoa, Italy
- M. Lambertini, Department of Internal Medicine and Medical Specialties (DiMI), School of Medicine, University of Genova, Genoa; Department of Medical Oncology, U.O.C. Clinica di Oncologia Medica, IRCCS Ospedale Policlinico San Martino, Genoa, Italy
Chapter 18. Breast cancer in the older population
- N.M.L. Battisti, Department of Medicine, Breast Unit, The Royal Marsden NHS Foundation Trust, Sutton, UK
- H. Wildiers, University Hospitals Leuven, Department of General Medical Oncology, Leuven, Belgium
Chapter 19. Locally recurrent disease
- H. Crezee, Department of Radiation Oncology, Amsterdam University Medical Centers/University of Amsterdam, Cancer Center Amsterdam, Treatment and Quality of Life, Cancer Biology and Immunology, Amsterdam, Netherlands
- O. Kaidar-Person, Breast Radiation Unit, Sheba Tel Hashomer, Ramat Gan; School of Medicine, Tel-Aviv University, Tel-Aviv, Israel
- P. Poortmans, Department of Radiation Oncology, Iridium Network, Wilrijk-Antwerp; Faculty of Medicine and Health Sciences, University of Antwerp, Antwerp, Belgium
Chapter 20. Survivorship and follow-up care
- M.A. Franzoi, Breast Cancer Survivorship Research Program – Unit INSERM 981, Gustave Roussy; Division of Interdisciplinary Patients Care Pathways (DIOPP), Gustave Roussy, Villejuif, France
- I. Vaz-Luis, Breast Cancer Survivorship Research Program – Unit INSERM 981, Gustave Roussy; Division of Interdisciplinary Patients Care Pathways (DIOPP), Gustave Roussy, Villejuif, France
